Effective Licensing in the Wake of MedImmune v. Genentech

The licensing of life science technologies, especially oncology-related technologies, is becoming an essential part of doing business. With MedImmune v. Genentech, the United States Supreme Court transformed the relationship between patent licensors and licensees. Historically, licensees were prevented from challenging patents on invalidity grounds. Now, a licensee may challenge a patent's validity while paying royalties to the licensor.

Although framed as a procedural question of standing to bring suit, the application of this Supreme Court case has the potential to shift the decision making of licensors and licensees and to significantly change the volume and cost of patent licensing activities. In this audio conference Dr. Samardija explores the Supreme Court decision and the various decisions that have followed, and provides attendees with 10 drafting tips to decrease the risks associated with a licensee challenging the validity of a patent.

Effective Licensing in the Wake of MedImmune v. Genentech was presented by Michael R. Samardzija, PhD, with Bracewell & Giuliani and aired on 2009-01-29. For more details or to download this conference, please visit our site at www.fxconferences.com